Melanotan-1: Dosing Protocols

Research Dosing Disclaimer#

The dosing information below is derived from research studies and is provided for educational purposes only. Melanotan-1 is not approved for human use, and no official dosing guidelines exist.

Dose-Response Data#

Objective: Provide dose–response data for Melanotan‑1 (afamelanotide; NDP‑α‑MSH) from animal studies, including specific doses with body‑weight adjustments and observed outcomes.

Evidence summary

• Mouse pigmentation (Ay/a mice): Subcutaneous NDP‑α‑MSH at 2 mg/kg administered over multiple consecutive days produced statistically significant coat darkening, indicating increased eumelanin production. Exact dosing frequency and study duration were truncated in the available text; body weights were not reported but dosing was already normalized to mg/kg. Outcome specifically noted as black coat/coat darkening in treated group(s).
• Guinea pig pharmacokinetics: Intraperitoneal Melanotan‑1 at 0.9 mg/kg was used to generate a plasma concentration–time profile. This excerpt did not report pigmentation outcomes for this i.p. dose.
• Guinea pig long‑acting depot: A fixed‑dose 4 mg subcutaneous implant/depot of Melanotan‑1 produced progressive visible pigmentation over 1–3 months, with increased eumelanin and objective luminance changes documented. Body weight was not reported; assuming a typical adult guinea pig of about 0.8 kg, this equates to an approximate single‑load of ~5 mg/kg. This conversion is approximate and for context, because the depot provides prolonged release rather than a single bolus.

Embedded comparative table of animal doses and outcomes

Interpretation and dose–response considerations

• Pigmentation efficacy threshold in mice: The 2 mg/kg s.c. regimen of NDP‑α‑MSH was sufficient to induce marked coat darkening in Ay/a mice, consistent with robust MC1R activation. Although only one explicit dose level (2 mg/kg) is available in the excerpt, the clear pigmentation response indicates that mg/kg‑scale parenteral dosing over several days can be effective in murine models.
• Depot vs bolus in guinea pigs: The 4 mg s.c. implant yielded sustained pigmentation with quantitative increases in eumelanin and decreases in luminance over months, supporting a dose–exposure–response relationship where continuous exposure produces durable pigmentation. Because body weight and release rate were not provided, mg/kg is approximated (~5 mg/kg for a typical 0.8 kg guinea pig), but the key observation is the time‑dependent increase in pigmentation under controlled‑release exposure.
• Systemic exposure without pigmentation readouts: The 0.9 mg/kg i.p. guinea pig study confirms systemic exposure at sub‑mg/kg to ~1 mg/kg bolus dosing, but pigmentation or photoprotection outcomes were not reported in that experiment fragment.

Limitations

• Several classical preclinical reports on Melanotan‑1 contain detailed dosing regimens and photoprotection endpoints (e.g., UV challenge) but were not fully retrievable in the current context. As a result, photoprotection dose–response metrics and multi‑dose comparisons beyond those listed above could not be extracted here. The mg/kg conversion for the implant study is approximate due to missing body weight and release‑rate details.

Administration Routes#

We compared pharmacokinetics and bioavailability of Melanotan‑1 (afamelanotide) across administration routes using human data where available and noting gaps.

Summary table

Narrative comparison

• Subcutaneous injection: Human studies report rapid absorption with approximately complete bioavailability relative to intravenous dosing, and a terminal (β‑phase) elimination half‑life of 1.3 ± 0.46 h. Distribution studies after s.c. dosing showed high levels in kidney and urine, consistent with predominant renal elimination. No Cmax, Tmax, or AUC values were reported in the available excerpts, but systemic exposure is clearly achieved with short plasma residence on the order of hours. Clinically, repeated s.c. dosing produced sustained tanning over weeks, reflecting pharmacodynamic persistence beyond plasma detectability.

• Intravenous reference: Early human work provides a terminal half‑life of 1.07 ± 0.46 h after IV administration, serving as a reference for elimination independent of absorption. No Cmax/Tmax/AUC values were reported.

• Subcutaneous implant (biodegradable PLGA/PLA; 16 mg marketed): Clinical PK sampling with the approved implant formulation showed that plasma afamelanotide was no longer measurable by day 14 post‑dose, while pharmacodynamic effects (skin darkening/photoprotection) persist for weeks to months. Quantitative implant PK parameters (Cmax, Tmax, AUC, apparent half‑life) were not reported in accessible sources; release is prolonged by design and systemic levels may be low/episodic.

• Oral administration: In a crossover study with oral 0.16 mg/kg dosing, afamelanotide was undetectable in plasma, indicating negligible oral bioavailability, likely due to peptide degradation and/or poor intestinal permeability.

• Intramuscular injection: We found no human PK or bioavailability data for intramuscular afamelanotide in the retrieved literature; therefore, route‑specific parameters (Cmax, Tmax, AUC, t1/2) cannot be provided.

• Topical administration: No human systemic PK data were identified for topical afamelanotide; systemic bioavailability and pharmacokinetics by this route remain uncharacterized in the evidence retrieved.

Interpretation

• Bioavailability hierarchy: Subcutaneous injection ≈ intravenous (complete), implant: not quantified but provides prolonged exposure with low/undetectable plasma after ~2 weeks, oral: negligible/undetectable, intramuscular/topical: no human data found.
• Pharmacokinetic profile: Afamelanotide exhibits a short terminal half‑life (~1 h) after IV/SC bolus dosing, with rapid absorption after SC injection and likely renal elimination. Implants produce sustained pharmacodynamic effects with limited plasma detectability at later time points; quantitative implant PK remains insufficiently described in accessible public reports.

Limitations

• Cmax, Tmax, AUC values were not reported in the accessible excerpts and may exist in unpublished sponsor reports (e.g., EMA EPAR appendices). We explicitly note the absence of human PK data for intramuscular and topical routes.

Human-Equivalent Dosing#

We summarize how preclinical animal doses of Melanotan‑1 (afamelanotide; NDP‑MSH) are translated to human‑equivalent doses (HED), and what allometric methods are used. We report explicit formulas, Km constants, worked examples, peptide‑specific considerations, and document an animal NDP‑MSH regimen alongside clinical human dose ranges.

Core allometric approaches used in the literature The predominant method is body‑surface‑area (BSA) based allometry using Km factors. The human‑equivalent dose (HED) in mg/kg is computed from an animal mg/kg dose by multiplying by the ratio of species Km values: HED (mg/kg) = Animal dose (mg/kg) × (Km_animal / Km_human). Km is defined as body weight (kg) divided by BSA (m2), and typical constants used are mouse Km = 3 and adult human Km = 37. This approach and its FDA endorsement are described broadly in methodological reviews and tools built on these factors (including a calculator implementation). Worked examples in the literature convert a murine dose using Km = 3 and human Km = 37 (e.g., 20 mg/kg mouse → 1.62 mg/kg HED; ≈113 mg total for a 70‑kg human). For first‑in‑human starting dose selection (MRSD), the HED derived from animal NOAEL is commonly divided by a safety factor (often ≈10), with case‑dependent adjustment. Some sources also report an alternate empirical expression when a species is not in the Km table: HED (mg/kg) = AED (mg/kg) × (animal BW/human BW)^0.33. Broader PK‑allometry and PBPK considerations are highlighted, noting that organ blood flows, tissue volumes, protein binding, transport, and disease state can meaningfully affect dose translation beyond BSA scaling.

Melanotan‑1 (afamelanotide) doses and how to scale them

• Preclinical animal regimen: In mice (C57BL/6J), NDP‑MSH 0.4 mg/kg was administered intraperitoneally daily in a neuroinflammation model (days 1–12). Applying BSA/Km scaling with mouse Km = 3 and adult human Km = 37 yields an illustrative HED of 0.4 × (3/37) ≈ 0.032 mg/kg. For a 70‑kg human, this corresponds to ≈2.2 mg total. This example is a direct allometric translation of a reported animal dose; the cited mouse study does not itself propose a human dose.
• Human clinical dosing context: Reviews of afamelanotide report human doses spanning 0.08–0.4 mg/kg across IV, oral, and subcutaneous routes, including schedules such as 10 daily injections of 0.08 mg/kg over 12 days and dose‑finding with 0.16, 0.26, and 0.4 mg/kg daily for 10 days. These human data provide context but are not back‑calculated from a specific animal regimen in the cited review pages.

What allometric scaling methods appear in the literature

• BSA/Km method (FDA‑endorsed): HED (mg/kg) = animal mg/kg × (Km_animal/Km_human). Typical Km: mouse 3, adult human 37; example conversions and tables are provided in methodological sources. Safety factors (often ≈10) are applied to HED from NOAEL to estimate MRSD for first‑in‑human.
• Alternate mass‑based exponent when Km tables are unavailable: HED (mg/kg) = AED (mg/kg) × (animal BW/human BW)^0.33. This is reported as an empirical alternative; BSA/Km remains the standard.
• PK‑informed scaling and PBPK: Reviews emphasize integrating PK/PD and physiologic parameters (organ blood flows, tissue volumes) when available, particularly for peptides, because metabolism (e.g., proteolysis), binding, and transport can alter exposure‑response relationships beyond what BSA scaling predicts.

Peptide‑specific considerations for afamelanotide Afamelanotide exhibits higher stability and activity than native α‑MSH and has shown distribution to multiple tissues in rodents after subcutaneous administration; however, across the excerpts retrieved there are limited peptide‑specific allometric formulae beyond BSA/Km, and no author‑provided direct animal‑to‑human scaling recipes for afamelanotide. Thus, the standard practice is to apply BSA/Km to animal mg/kg doses to estimate HED, then refine with PK/PD or PBPK data if available and apply safety factors for MRSD when planning first‑in‑human studies.

Supporting artifact

Conclusion In practice, animal doses of Melanotan‑1 (afamelanotide/NDP‑MSH) are translated to human‑equivalent doses using BSA/Km allometry: HED (mg/kg) = animal dose × (Km_animal/Km_human), with mouse Km ≈ 3 and adult human Km ≈ 37, followed by application of a safety factor (commonly ≈10) for MRSD. An example mouse regimen of 0.4 mg/kg i.p. scales to an HED ≈ 0.032 mg/kg. Literature also notes an alternate 0.33 mass‑exponent expression for HED when Km tables are unavailable and recommends PK/PD or PBPK refinement, especially for peptides. Human clinical experience documents afamelanotide doses in the 0.08–0.4 mg/kg range across routes, providing context rather than a direct allometric derivation from preclinical studies.

Evidence Gaps#

• No human dose-finding studies have been completed
• Allometric scaling from animal models has inherent limitations
• Route-specific bioavailability data in humans is absent
• Optimal treatment duration has not been established

Related Reading#

• Melanotan-1 overview and research guide
• Melanotan-1 side effects profile
• Melanotan-1 research evidence